Method of treating chronic fatigue syndrome using an opiate receptor antagonist
Patent 5013739 Issued on May 7, 1991. Estimated Expiration Date: 
November 8, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 8, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesProcess for using endogenous enkephalins and endorphins to stimulate the immune system Method of treatment for autoimmune diseases Method of treatment for arthritic and inflammatory diseases Patent #: 4863928 InventorsApplicationNo. 433152 filed on 11/08/1989US Classes:514/282One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.)ExaminersPrimary: Robinson, Allen J.Assistant: Hollinden, Gary E. Attorney, Agent or FirmInternational ClassA61K 031/44AbstractChronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic fatigue syndrome, chronic inflammatory connective tissue disease, including rheumatoid arthritis and systemic lupus erythematous and related diseases, and multiple sclerosis are treated by the administration via a pharmacologically effective route of an essentially pure opiate receptor antagonist, preferably an essentially pure opiate receptor antagonist exhibiting a substantially higher blocking effectiveness against Mu opiate receptor sites than against Delta receptor sites, exemplified by naltrexone and naloxone, at a low dose concentration, corresponding to about 1-10 mg per day for naltrexone, at which concentration Delta blocking activity is small, while Mu blocking activity is significant.Other References
| |
